title: Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
abstract: We have shown that following priming with replicating adenovirus type 5 host range mutant (Ad5hr)-human immunodeficiency virus (HIV)/simian immunodeficiency virus (SIV) recombinants, boosting with gp140 envelope protein enhances acute-phase protection against intravenous simian/human immunodeficiency virus (SHIV)(89.6P) challenge compared to results with priming and no boosting or boosting with an HIV polypeptide representing the CD4 binding site of gp120. We retrospectively analyzed antibodies in sera and rectal secretions from these same macaques, investigating the hypothesis that vaccine-elicited nonneutralizing antibodies contributed to the better protection. Compared to other immunized groups or controls, the gp140-boosted group exhibited significantly greater antibody activities mediating antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated viral inhibition (ADCVI) in sera and transcytosis inhibition in rectal secretions. ADCC and ADCVI activities were directly correlated with antibody avidity, suggesting the importance of antibody maturation for functionality. Both ADCVI and percent ADCC killing prechallenge were significantly correlated with reduced acute viremia. The latter, as well as postchallenge ADCVI and ADCC, was also significantly correlated with reduced chronic viremia. We have previously demonstrated induction by the prime/boost regimen of mucosal antibodies that inhibit transcytosis of SIV across an intact epithelial cell layer. Here, antibody in rectal secretions was significantly correlated with transcytosis inhibition. Importantly, the transcytosis specific activity (percent inhibition/total secretory IgA and IgG) was strongly correlated with reduced chronic viremia, suggesting that mucosal antibody may help control cell-to-cell viral spread during the course of infection. Overall, the replicating Ad5hr-HIV/SIV priming/gp140 protein boosting approach elicited strong systemic and mucosal antibodies with multiple functional activities associated with control of both acute and chronic viremia.
authors.affiliation: NIH, NCI, 41 Medlars Drive, Building 41, Room D804, Bethesda, MD 20892-5065, USA.
authors.forename: Peng
authors.initials: P
authors.lastname: Xiao
authors.forename: Jun
authors.initials: J
authors.lastname: Zhao
authors.forename: L Jean
authors.initials: LJ
authors.lastname: Patterson
authors.forename: Egidio
authors.initials: E
authors.lastname: Brocca-Cofano
authors.forename: David
authors.initials: D
authors.lastname: Venzon
authors.forename: Pamela A
authors.initials: PA
authors.lastname: Kozlowski
authors.forename: Rachmat
authors.initials: R
authors.lastname: Hidajat
authors.forename: Thorsten
authors.initials: T
authors.lastname: Demberg
authors.forename: Marjorie
authors.initials: M
authors.lastname: Robert-Guroff
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D015686:Gene Products, env / Q000276:immunology*; D006678:HIV / Q000276:immunology*; D015483:HIV Antibodies / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology*; D006801:Humans; D007114:Immunization; D007117:Immunization, Secondary; D008253:Macaca mulatta; D008297:Male; D012007:Rectum / Q000276:immunology / Q000821:virology; D018449:SAIDS Vaccines / Q000276:immunology; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology; D015302:Simian Immunodeficiency Virus / Q000276:immunology*; D014766:Viremia / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D053586:Virus Internalization
chemical_list: D016915:AIDS Vaccines; D015686:Gene Products, env; D015483:HIV Antibodies; D018449:SAIDS Vaccines
references.citation: J Virol. 2004 Mar;78(6):3140-4
references.pmid: 14990733
references.citation: Nat Med. 2009 Jan;15(1):34-41
references.pmid: 19079256
references.citation: J Immunol. 2006 Sep 15;177(6):4028-36
references.pmid: 16951366
references.citation: Science. 2008 May 9;320(5877):760-4
references.pmid: 18467582
references.citation: Nat Med. 1997 Jun;3(6):651-8
references.pmid: 9176492
references.citation: Cell. 1991 Dec 20;67(6):1121-9
references.pmid: 1760840
references.citation: Vaccine. 2005 Mar 31;23(19):2522-9
references.pmid: 15752839
references.citation: J Infect Dis. 2004 Dec 1;190(11):1970-8
references.pmid: 15529262
references.citation: J Virol. 1999 May;73(5):4009-18
references.pmid: 10196297
references.citation: Virology. 2008 Dec 20;382(2):217-25
references.pmid: 18947849
references.citation: Virology. 2006 Sep 15;353(1):83-98
references.pmid: 16814356
references.citation: Curr Opin HIV AIDS. 2009 Sep;4(5):388-93
references.pmid: 20048702
references.citation: Nat Med. 2000 Jun;6(6):607-8
references.pmid: 10835650
references.citation: J Biol Chem. 1996 Jul 26;271(30):17990-5
references.pmid: 8663408
references.citation: Nat Med. 2002 Feb;8(2):150-6
references.pmid: 11821899
references.citation: J Immunol Methods. 2006 Jan 20;308(1-2):53-67
references.pmid: 16343526
references.citation: Nature. 2008 Oct 2;455(7213):613-9
references.pmid: 18833271
references.citation: Nat Med. 2000 Feb;6(2):200-6
references.pmid: 10655110
references.citation: Nat Med. 2009 Mar;15(3):293-9
references.pmid: 19219024
references.citation: J Immunol. 2004 Mar 15;172(6):3745-57
references.pmid: 15004179
references.citation: J Virol. 2009 Jul;83(13):6508-21
references.pmid: 19403685
references.citation: J Virol. 1997 Nov;71(11):8531-41
references.pmid: 9343211
references.citation: Nat Med. 2003 Jul;9(7):847-52
references.pmid: 12835704
references.citation: Science. 2001 Apr 6;292(5514):69-74
references.pmid: 11393868
references.citation: Nat Rev Immunol. 2005 Oct;5(10):783-92
references.pmid: 16200081
references.citation: Nat Med. 2002 Feb;8(2):114-6
references.pmid: 11821891
references.citation: J Immunol. 2005 Feb 15;174(4):2185-9
references.pmid: 15699150
references.citation: AIDS Rev. 2003 Jul-Sep;5(3):178-85
references.pmid: 14598567
references.citation: J Exp Med. 2009 May 11;206(5):1117-34
references.pmid: 19414559
references.citation: Curr HIV Res. 2008 Nov;6(6):515-9
references.pmid: 18991616
references.citation: J Immunol. 2007 May 15;178(10):6596-603
references.pmid: 17475891
references.citation: Mucosal Immunol. 2009 Sep;2(5):412-26
references.pmid: 19587640
references.citation: Virology. 2008 May 10;374(2):322-37
references.pmid: 18252262
references.citation: J Virol. 2004 Mar;78(5):2212-21
references.pmid: 14963117
references.citation: N Engl J Med. 2009 Dec 3;361(23):2209-20
references.pmid: 19843557
references.citation: J Immunol. 2000 Nov 1;165(9):5170-6
references.pmid: 11046049
references.citation: Nature. 2007 Sep 6;449(7158):101-4
references.pmid: 17805298
references.citation: Vaccine. 2004 Dec 16;23(5):615-22
references.pmid: 15542181
references.citation: AIDS Res Hum Retroviruses. 1989 Dec;5(6):557-63
references.pmid: 2692657
references.citation: AIDS Res Hum Retroviruses. 2002 Nov 1;18(16):1197-205
references.pmid: 12487826
references.citation: J Immunol. 1996 Sep 1;157(5):2168-73
references.pmid: 8757343
references.citation: J Virol. 2009 May;83(9):4102-11
references.pmid: 19224993
references.citation: AIDS Res Hum Retroviruses. 1990 Mar;6(3):341-56
references.pmid: 1971182
references.citation: J Virol. 2006 Sep;80(18):9217-25
references.pmid: 16940533
references.citation: Science. 2000 Oct 20;290(5491):486-92
references.pmid: 11039923
references.citation: Nature. 1984 Nov 15-21;312(5991):271-5
references.pmid: 6504141
references.citation: J Virol. 2001 Aug;75(15):6953-61
references.pmid: 11435575
references.citation: J Virol. 2007 Apr;81(7):3414-27
references.pmid: 17229693
references.citation: Science. 1989 Jun 9;244(4909):1152-7
references.pmid: 2658060
references.citation: J Immunol. 2001 May 15;166(10):6257-65
references.pmid: 11342649
references.citation: Immunity. 1998 Aug;9(2):277-87
references.pmid: 9729048
references.citation: Nat Med. 1997 Jan;3(1):42-7
references.pmid: 8986739
references.citation: Mucosal Immunol. 2009 Nov;2(6):536-50
references.pmid: 19741603
references.citation: Nat Rev Immunol. 2006 Dec;6(12):930-9
references.pmid: 17124514
references.citation: Nat Med. 2000 Feb;6(2):207-10
references.pmid: 10655111
references.citation: Vaccine. 2003 May 16;21(17-18):2190-6
references.pmid: 12706710
references.citation: J Virol. 2004 Jul;78(14):7490-7
references.pmid: 15220422
references.citation: J Clin Immunol. 2001 May;21(3):227-33
references.pmid: 11403230
references.citation: Expert Opin Biol Ther. 2008 Sep;8(9):1347-63
references.pmid: 18694354
references.citation: J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):270-7
references.pmid: 16940858
references.citation: Nat Med. 1999 Feb;5(2):204-10
references.pmid: 9930869
references.citation: J Immunol. 2009 Mar 15;182(6):3718-27
references.pmid: 19265150
references.citation: J Virol. 2009 Jan;83(2):791-801
references.pmid: 18971271